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Background. Reactive oral fluid and whole blood rapid HIV tests must be followed with a confirmatory test (Western blot
(WB), immunofluorescent assay (IFA) or approved nucleic acid amplification test (NAAT)). When the confirmatory result is
negative or indeterminate (i.e. discordant with rapid result), repeat confirmatory testing should be conducted using a follow-
up specimen. Previous reports have not described whether repeat testing adequately resolves the HIV-infection status of
persons with discordant results. Methodology. Post-marketing surveillance was conducted in 368 testing sites affiliated with
14 state and 2 city health departments from August 11, 2004 to June 30, 2005 and one health department through December
31, 2005. For persons with discordant results, data were collected on demographics, risk behaviors, HIV test results and
specimen types. Persons with repeat confirmatory results were classified as HIV-infected or uninfected. Regression models
were created to assess risk factors for not having repeat testing. Principal Findings. Of 167,371 rapid tests conducted, 2589
(1.6%) were reactive: of these, 2417 (93%) had positive WB/IFA, 172 (7%) had negative or indeterminate WB/IFA. Of 89/172
(52%) persons with a repeat confirmatory test: 17 (19%) were HIV-infected, including 3 with indeterminate WB and positive
NAAT; 72 (81%) were uninfected, including 12 with repeat indeterminate WB. Factors associated with HIV-infection included
having an initial indeterminate WB/IFA (vs. negative) (p,0.001) and having an initial oral fluid WB (vs. serum) (p,0.001).
Persons who had male-female sex (vs. male-male sex) were at increased risk for not having a repeat test [adjusted OR 2.6, 95%
CI (1.3, 4.9)]. Conclusions. Though only half of persons with discordant results had repeat confirmatory testing, of those who
did, nearly one in five were HIV-infected. These findings underscore the need for rapid HIV testing programs to increase repeat
confirmatory testing for persons with discordant results. Because of the lower sensitivity of oral fluid WBs, confirmatory testing
following a reactive rapid test should be conducted using serum or plasma, when possible.
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Blood and Oral Fluid Rapid HIV Test Results: Findings from Post Marketing Surveillance. PLoS ONE 3(2): e1524. doi:10.1371/journal.pone.0001524
INTRODUCTION
The OraQuick Rapid HIV Antibody Test (OraQuick) was the first
HIV rapid test to be approved by the Food and Drug
Administration (November 2002) and to be waived under the
Clinical Laboratory Improvement Amendments of 1988 (CLIA)
(February 2003) for use at point of care [1,2]. The Centers for
Disease Control and Prevention (CDC) initiated surveillance to
assess the accuracy of waived rapid HIV testing. The OraQuick
test performs within the manufacturer’s claim with few false
positives when used on whole blood (specificity 99.90% to 99.98%)
and oral fluid (specificity 99.60% to 99.89%), though clusters of
false positives and false negatives may occur [3–8]. HIV
prevalence in the population being tested can affect test
performance, particularly positive predictive value, the probability
that a person actually has HIV given that he or she tests positive
[7]. Per the manufacturer’s instructions, the rapid test is typically
run in singlet [3], and all reactive (preliminary positive) rapid test
results should be confirmed with either a WB, IFA, or approved
NAAT test [9]. In cases where the confirmatory test result is
discordant with the reactive rapid test result (i.e., the WB or IFA is
negative or indeterminate), a repeat confirmatory test should be
performed on a new follow-up specimen [9,10].
Repeat confirmatory testing is important to rule out labeling or
laboratory error as the reason for the discordant test result. It is
also needed if the screening test is more sensitive than the
supplemental test used to confirm infection. Differences in
sensitivity between the screening and confirmatory tests may be
particularly important for programs that use a rapid test on whole
blood for screening and a WB on oral fluid for confirmation.
Compared with assays performed on whole blood, serum, or
plasma, assays performed on oral fluid have a lower sensitivity due
to the lower antibody concentration found in oral fluid [11–14].
Therefore, a blood specimen obtained during a follow-up visit is
recommended for repeat confirmatory testing for persons who
have a preliminary positive rapid test result followed by an initial
confirmatory test result that is not positive [9,10].
Since the widespread use of rapid tests began in publicly funded
HIV test programs in 2003, no reports have described (1) whether
current testing guidelines for repeat confirmatory testing are
adequate for resolving the infection status of clients with discordant
test results and (2) the magnitude and correlates of not having repeat
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[15]. One report with a small number of discordant cases
characterized the infection status of persons with discordant results
who had repeat confirmatory testing but did not examine correlates
of not having repeat testing [10]. Information on whether HIV
infection status is resolved for persons with initially discordant test
results who adhere to guidelines for repeat confirmatory testing is
important for guiding public health rapid HIV test programs,
especially those that use oral fluid for initial WB confirmation and
those that have experienced excessive discordant test results [4–7].
This report uses data obtained from CDC’s Post Marketing
Surveillance Program to evaluate the HIV infection status of
persons with reactive rapid HIV results and discordant confirma-
tory test results who have repeat confirmatory testing. We also
assess the magnitude and correlates of not having repeat testing.
METHODS
Surveillance System
Rapid test post marketing surveillance was conducted in 368 rapid
HIV test sites affiliated with 14 state (Arizona, Delaware, Florida,
Indiana, Louisiana, Massachusetts, Michigan, Montana, Nebraska,
New Jersey, New York, North Carolina, Utah, Wisconsin) and 3 city
(Chicago, New York City, San Francisco) health departments from
August 11, 2004 to June 30, 2005. These health departments were
chosen based on their applications to CDC in which they
demonstrated their ability to conduct rapid testing. Surveillance
continued in one city health department through December 31,
2005 in response to a cluster of false-positive rapid test results at one
test site [7]. Health departments selected rapid test sites within their
jurisdiction to participate in surveillance. Whole blood (collected by
fingerstick and venipuncture) and oral fluid rapid tests routinely
conducted at each site were included in surveillance. Although all
health departments, except three (Delaware, Massachusetts, and
Montana), offered whole blood and oral fluid rapid tests in at least
one of their sites during surveillance, information on whether each
person tested was offered both whole blood and oral fluid rapid
testing was not collected on a case-by-case basis. Post marketing
surveillance was determined not to be research by CDC since it
consisted of routine public health disease surveillance, and therefore
Institutional Review Board approval was not required by CDC.
Oral fluid or blood specimens from clients with reactive rapid
tests were submitted to local laboratories for enzyme immunoassay
(EIA) screening (optional) followed by WB or IFA confirmation
(initial confirmatory testing). CDC recommended that all persons
with discordant results return for repeat confirmatory testing,
preferably with a blood specimen [9,10]. Local laboratories used
FDA-approved EIA, WB, IFA and nucleic acid amplification
(NAAT) tests in accordance with local procedures. For all persons
with a reactive rapid test result followed by a negative or
indeterminate confirmatory test, case report forms which included
information on patient demographics, HIV risk behaviors, and
initial and repeat HIV test results were completed and submitted
to CDC. Two health departments collected data on the
appearance of test lines on rapid test devices that produced
discordant test results from January 1, 2005 to June 30, 2005.
Affiliated laboratories of participating health departments sent to
CDC available remnant serum or plasma from initial or repeat
specimens collected from persons with discordant rapid test results.
Remnant oral fluid specimens were not submitted because they
cannot be stored as long or undergo as many freeze-thaw cycles as
blood or plasma [11]. From September to November 2005,
interviews were conducted with principal investigators from
participating health departments to assess the completeness of
discordant case reporting and to assess reasons for not obtaining
repeat confirmatory specimens.
At CDC, remnant serum was tested by the third-generation
Genetic Systems HIV-1/HIV-2 Plus O EIA, and Calypte HIV-1 or
Genetic Systems HIV-1 WB. Western blot tests were run at CDC
even if an EIA was negative. If remnant plasma was sent, it was
tested individually using the Roche Cobas Amplicor HIV-1 Monitor
Assay. If plasma was not sent, a qualitative NAAT for HIV-1 RNA
(Gen-Probe Procleix HIV-1 RNA Assay) was run off-label on
remnant sera.HIV RNA detection using Gen-ProbeProcleixHIV-1
RNA Assay was performed in pools of up to 16 serum specimens.
Analyses
To evaluate the infection status of those who underwent repeat
confirmatory testing, we classified persons as: (1) uninfected (false
positive rapid test result) if the last repeat EIA was negative (if
performed) and the last repeat WB or IFA was negative or
indeterminate, and HIV-1 RNA was not detected in any initial or
repeat confirmatory specimens if tested with NAAT; and (2)
infected (true positive rapid test result), if the WB conducted at
CDC on an initial or repeat confirmatory specimen was positive or
if the IFA or WB conducted on a repeat confirmatory specimen at
the participating laboratory was positive, or if HIV-1 RNA was
detected at a local laboratory or at CDC on either the initial or
repeat confirmatory specimen. Since indeterminate Western blot
test results can occur in uninfected persons, we chose to classify as
not infected those persons whose repeat confirmatory WB or IFA
test was indeterminate provided other serologic or nucleic acid
tests did not suggest infection [16,17]. For HIV-1 uninfected and
infected, we report the type of initial and repeat confirmatory
specimens that were obtained; available initial and repeat
confirmatory serologic and nucleic acid test results; and the
interval in days from the initial confirmatory test to the last repeat
confirmatory test for persons classified as not infected, and first
positive confirmatory test for persons classified as infected. We also
report available test line appearance for rapid test devices of
persons with discordant test results.
In univariate analyses, we used Mantel-Haenszel chi square tests
and odds ratios with 95% confidence intervals to assess
demographic, behavioral, and initial testing correlates of not
having repeat confirmatory testing. Effect modification was
assessed using the Breslow Day test. Variables which were
associated (p,0.2) with not having repeat confirmatory testing
in univariate analysis were included in the multivariate logistic
regression model. Goodness of fit was assessed using the likelihood
ratio test. Analyses were performed using SAS version 9.1 (SAS
Institute, Cary, North Carolina, USA).
RESULTS
There were 167,371 rapid tests (136,798 whole blood and 30,573
oral fluid) conducted during the post marketing surveillance
period, including the extended surveillance in one health
department. There were 2589 (1.6%) reactive rapid tests; of these,
2417 (93%) had confirmatory test results that were positive (2033
whole blood rapid, 384 oral fluid rapid) and 172 (7%) had
confirmatory test results that were negative or indeterminate (72
whole blood rapid and 100 oral fluid rapid). Of the 172 persons
with discordant test results, 74% were male; 50% were 33 years
old or younger (range 15 to 82); 45% were white, non-Hispanic,
31% were black, non-Hispanic, 10% were other race, non-
Hispanic, and 13% were Hispanic. The gender, age and race of
persons presenting for rapid testing at all post marketing
surveillance sites were described previously [7].
Discordant Rapid HIV Results
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Outcomes
Testing practices Of the 172 persons with discordant test results,
89 (52%) had $1 repeat confirmatory tests conducted and 83 (48%)
did not have repeat testing (Figure 1). Overall, 83 (93%) of 89
persons with a repeat confirmatory test had a repeat confirmatory
test performed on a serum specimen, including 18 whose initial
confirmatory test was conducted using oral fluid (Figure 1).
Of the 83 persons on whom a repeat confirmatory test was not
done, most 66 (80%) had an initial confirmatory WB/IFA
performed on serum, including 1 initial indeterminate which was
classifiedasWesternblotpositiveatCDC.Withtheexceptionofthat
individual, the HIV-infection status of these persons is not known.
Repeat testing HIV-1 infection outcomes Of the 89
persons with a discordant confirmatory test result on whom $1
repeat confirmatory tests were conducted, 72 (81%) were classified
as uninfected (false-positive rapid test result) and 17 (19%) were
classified as HIV-1 infected (true-positive rapid test result). Those
whose initial confirmatory WB/IFA result was indeterminate were
more likely to be HIV-infected (15/24 63%) compared with those
whose initial confirmatory WB/IFA result was negative (2/65 3%)
(p,0.001). Those whose initial confirmatory test was conducted
on oral fluid were more likely to be HIV-infected based on repeat
confirmatory testing (13/23 57%) compared with those whose
initial confirmatory test was conducted on serum (2/64 3%)
(p,0.001). The association between initial confirmatory specimen
type and follow-up HIV-infection status remained statistically
significant when stratified by whether initial confirmatory test
result was negative or indeterminate (data not shown).
HIV-1 uninfected (False-positive rapid test) Of the 72
persons classified as uninfected, 29 (40%) had a whole blood rapid
test and 43 (60%) had an oral fluid rapid test.
Of the 60 persons classified as uninfected whose repeat WB/
IFA test result was negative, 57 (95%) had EIAs performed at the
local laboratory on the initial confirmatory specimen, and of these,
1 (2%) was reactive; 47 (78%) had EIAs performed on the repeat
confirmatory specimen at the local laboratory, and of these, 1 (2%)
was repeatedly reactive. For these 60 uninfected persons, the
median interval in days between the initial confirmatory test and
the last repeat negative confirmatory test was 36 (range: 6-235). Of
these 60, 23/23 (100%) had undetectable virus based on Procleix
testing on remnant serum, including 12 who had a short interval
between initial confirmatory test and last repeat negative
confirmatory test (,=36 days).
Of the 12 persons classified as uninfected who had a repeat
confirmatory WB test result that was indeterminate, 12/12 (100%)
had a repeat negative EIA at the local laboratory, 8/9 (89%) had a
repeat negative EIA at CDC, 6/6 (100%) had a repeat negative
IFA, and 7/7 (100%) had a negative NAAT result on either the
initial or repeat confirmatory specimen or both (Table 1). The
median interval between the initial confirmatory test and the last
repeat indeterminate WB for these 12 persons was 24 days (range:
7–81 days). Of the 7 persons with negative NAAT results, 3 had a
short interval between initial confirmatory test and last repeat
negative confirmatory tests (,=24 days).
Of the 72 persons classified as uninfected based on repeat
confirmatory testing, 31 (43%) had OraQuick test-line appearance
recorded; of these, 25 (81%) had a very faint test line (24 oral, 1
whole blood), 2 (7%) had a faint line (both oral), and 4 (13%) had a
reddish test line (1 whole blood, 3 oral).
HIV-1 infected (True-positive rapid test) Of the 17
persons classified as infected, 12 (71%) had a whole blood rapid
test and 5 (29%) had an oral fluid rapid test.
Of the 17 persons with repeat confirmatory testing who were
classified as HIV-1 infected, 15 (88%) had an initially indeterminate
WB. Thirteen (76.5%) had initial confirmatory tests performed on
oral fluid. Of these 13, 8 (62%) were EIA negative and 2 (15%) were
WBnegative(Table2).FourpersonswhohadaninitialnegativeEIA
and indeterminate WB on oral fluid had a repeatedly reactive EIA
and positive WB on serum performed 1 to 8 days after the initial
confirmatory test (Table 2). Of the 4 persons whose initial
confirmatory specimen was serum, 1 of 4 (25%) tested EIA-negative,
and 4/4 tested either IFA or WB indeterminate at the local
laboratory. Of the 17 persons classified as HIV-infected, 3 (18%)
were classified based on the detection of HIV-1 RNA following an
indeterminate Western blot (Table 2). Of the 17 persons classified as
infected,5(29%)hadappearanceoftheOraQuicktestlinerecorded:
2 (40%) had very faint test lines (1 oral-fluid, 1 whole blood) and 3
(60%) had a reddish test line (1 whole blood, 2 oral fluid).
Failure to Have Repeat Confirmatory Testing
In univariate analysis, the following characteristics were associated
(p,0.2) with increased risk of not having repeat confirmatory testing
and were included in the multivariable model: having male-female
sex (compared with male-male sex), not having a previous HIV test,
and having a negative initial confirmatory result (compared with
indeterminate) (Table 3). Not having a previous HIV test was
removed from the model due to its high correlation with history of
male-female sex. In multivariate analysis, having male-female sex
(compared with male-male sex) was associated (p,0.05) with
increased risk of not having repeat confirmatory testing.
Reasons for not obtaining repeat confirmatory test
specimens
Thirteen of eighteen health departments had at least one
discordant case that did not have repeat confirmatory testing.
Principal investigators from these health departments gave the
Figure 1. Repeat confirmatory testing practices after a reactive rapid
HIV test and negative or indeterminate WB/IFA. WB=Western blot,
IFA=Immunofluorescent assay, OF=oral fluid, IND=indeterminate,
NEG=negative.
doi:10.1371/journal.pone.0001524.g001
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Discordant Rapid HIV Results
PLoS ONE | www.plosone.org 5 February 2008 | Issue 2 | e1524following reasons for not repeating confirmatory testing on
discordant clients: unable to locate clients (6/13 (46%) health
departments), client did not return for testing (5/13 (39%) health
departments), client refused (1/13 (8%) health departments) and
unknown (3/13 (23%) health departments).
DISCUSSION
Despite national guidelines in the United States (U.S.) recom-
mending repeat confirmatory testing for persons with a reactive
rapid test result and negative or indeterminate confirmatory test
result, only half of the persons with discordant test results had a
repeat confirmatory test during post-marketing surveillance [9,10].
The importance of repeat confirmatory testing is clear given our
finding that overall nearly one in five persons with discordant test
results who underwent repeat confirmatory testing were found to
be HIV-infected, including over half of those whose initial
confirmatory test was WB/IFA indeterminate. In addition, repeat
confirmatory testing identified two HIV-infected persons whose
initial Western blot results were negative. Repeat confirmatory
testing is particularly important for persons with discordant HIV
test results who were initially confirmed with an oral fluid
specimen: over half of persons who tested rapid test reactive who
had a negative or indeterminate WB performed on oral fluid were
found to be HIV-infected. Based on these findings and given the
higher sensitivity of blood tests compared with oral fluid tests,
testing with blood for the initial and repeat confirmatory tests
following a reactive rapid test is preferable, when possible. Our
Table 3. Demographic, risk, and initial test characteristics of 172 persons with reactive rapid HIV test result and negative or
indeterminate confirmatory test and proportion without a repeat confirmatory test; 17 health departments, 11 August 2004 to 31
December 2005.
a
..................................................................................................................................................
Did not have repeat
confirmatory test n/N (%)
Univariate OR
(95% CI)
Univariate
p-value
Multivariate aOR
(95% CI)
Multivariate
p-value
Sex
Female 24/45 (53.3) 1.0
Male 59/127 (46.5) 0.76 (0.38, 1.50) p=0.428 –
Age Group
,33 38/84 (45.2) 1.0 –
.=33 43/85 (50.6) 1.24 (0.68, 2.27) p=0.486
Race/Ethnicity
White non-Hispanic 35/78 (44.9) 1.0
Black non-Hispanic 28/53 (52.8) 1.38 (0.68, 2.77) p=0.372 –
Other non-Hispanic 9/17 (52.9) 1.38 (0.48, 3.96) p=0.546
Hispanic 10/22 (45.5) 1.02 (0.40, 2.65) p=0.961
Sexual Behavior
Male-male sex 22/65 (33.9) 1.0 1.0
Male-female sex 59/103 (57.3) 2.62(1.38, 5.00) p=0.003* 2.55 (1.33, 4.89)
a p=0.005*
Injection drug use
No injection drug use 68/143 (47.6) 1.0 –
Injection drug use 13/25 (52.0) 1.20 (0.51, 2.80) p=0.681
Previously HIV Tested
Yes 55/127 (43.3) 1.0 –
No 27/41 (65.9) 2.52 (1.21, 5.26) p=0.014*
Initial confirmatory specimen –
Serum/plasma 66/132 (50.0) 1.35 (0.66, 2.76) p=0.407
Oral Fluid 17/40 (42.5) 1.0
Initial rapid HIV test context –
Confidential 50/101 (49.5) 1.0
Anonymous 31/69 (44.9) 0.83 (0.45, 1.54) p=0.557
Initial confirmatory test
Negative 69/134 (59.5) 1.82 (0.87, 3.82) p=0.113 1.89 (0.87, 4.10)
b, p=0.108
Indeterminate 14/38 (36.8) 1.0 1.0
Site type
Non-traditional site (Outreach/prison/other) 16/36 (44.4) 1.0 –
Traditional clinic site 63/128 (49.2) 1.21 (0.58, 2.55) p=0.613
aOR, adjusted odds ratio; CI, confidence interval.
*Statistically significant
aadjusted for initial confirmatory test result
badjusted for sexual behavior
doi:10.1371/journal.pone.0001524.t003
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Discordant Rapid HIV Results
PLoS ONE | www.plosone.org 6 February 2008 | Issue 2 | e1524findings on the high proportion of persons with discordant test
results who do not have repeat confirmatory testing and the
prevalence of HIV infection among persons with discordant rapid
test results suggest that some HIV-infected persons with discordant
results may be misinformed that they are uninfected based on the
results of a single, initial confirmatory test result that is negative.
These findings underscore the need for state and local rapid HIV
testing programs to work with persons with discordant rapid HIV
test results to ensure that they have repeat confirmatory testing.
Persons with discordant rapid HIV test results who had male-
female sex were at higher risk for not having repeat confirmatory
testing. It is possible that some of these testers were perceived to be
of lower HIV risk than men who have sex with men, so their rapid
test result was viewed as false positive based on the initial negative
or indeterminate confirmatory test. Also, principal investigators of
participating health departments indicated that not being able to
locate clients or clients not returning for testing were the primary
reasons for clients not having repeat confirmatory testing. A
significant proportion (37%) of those without a repeat confirma-
tory test tested anonymously so they could not be reached for
further testing. To increase repeat confirmatory testing, testing
staff should encourage all persons with discordant HIV test results
to have repeat confirmatory testing done at the visit during which
they receive their initial negative or indeterminate confirmatory
results. However, additional repeat testing may be necessary to
allow sufficient time for seroconversion [18].
Given the well-publicized clusters of excess false-positive oral fluid
rapid test results, some counseling and testing staff may also have
been less concerned about recommending repeat confirmatory
testing for clientswho initially had anunconfirmedreactive oral fluid
rapid test result [4–7]. Reactive rapid test results that do not confirm
positive should not be presumed to be false positive. Of those with
discordant test results determined to be HIV-infected, at least two
had OraQuick test lines reported to be very faint (one whole blood
and one oral fluid). Upon seeing any OraQuick test line, including
those which are very faint, it is necessary to pursue confirmatory
testing andrepeatconfirmatory testing (if warranted)and notassume
that the rapid test is false positive.
Of the HIV-infected persons with initially discordant confirma-
tory test results, four persons with an indeterminate WB on oral
fluid had a positive WB on serum less than 9 days after the initial
confirmatory test. In addition, compared with those who initially
confirmed with serum, proportionally more persons with reactive
rapid test results who initially confirmed WB negative or
indeterminate on oral fluid were found to be HIV-infected on
follow-up. This is likely due to the decreased sensitivity of the oral
fluid test relative to serum, and it underscores the need to use
serum or plasma for confirmatory tests when possible due to the
lower concentration of antibody in oral fluid compared with serum
or plasma [9–13]. We were encouraged to find that among those
clients who underwent repeat confirmatory testing, most did so
with a blood specimen.
Rapid HIV test providers should also be aware that some HIV-
infected clients with discordant test results may take time to fully
seroconvert, even when repeat confirmatory tests are performed on
serum or plasma. Of note, one initially discordant rapid test client
had negative results for both a serum EIA and IFA performed
42 days after a reactive oral-fluid rapid test result. In the absence of
an indeterminate WB conducted at the time of the negative EIA and
negative IFA and a detectable NAAT conducted 10 days later, this
apparently HIV-infected person would have been informed that he
was not infected according to current U.S. confirmation guidelines
[9,18]. The possibility exists, though, that this infection was acquired
after the initial reactive rapid test. Additionally, two other persons
with discordant rapid test results who were classified as HIV-infected
had an indeterminate repeat WB and a detectable NAAT. In these
three cases, NAAT provided further information about infection
status beyond WB test results. Since the publication of rapid test
confirmation recommendations in 2003, one NAAT has been
approved by the FDA for HIV diagnostic confirmation [19]. Thus,
NAAT should be considered in addition to WB or IFA for repeat
confirmatory testing to help resolve the infection status of persons
with discordant rapid HIV test results. It’s important to note that a
detectable NAAT may indicate infection, though an undetectable
result does not verify a lack of infection [19].
Among those with discordant test results who had repeat
confirmatory tests, most (80%), were found to be HIV uninfected.
Of those classified as HIV uninfected, twelve persons who did not
have evidence of HIV infection based on negative EIA, IFA, and
NAAT results at their repeat test had an indeterminate repeat WB
result. Only one of the twelve developed a major HIV band (p24)
during follow-up, which can occur in uninfected persons [16]. This
person had a non-reactive EIA on repeat testing, which provided
evidence that they were likely uninfected, though a repeat WB
conducted on serum or NAAT on plasma may have provided
more information. Because of the high prevalence of indetermi-
nate WB results among persons who are not HIV-infected, the use
of other confirmatory assays should be considered [17].
This surveillance project was subject to some limitations which
should be mentioned. Local laboratories utilized a variety of EIA,
WB and NAAT tests which have varying sensitivities and
specificities, and repeat tests were conducted at varying intervals
after the initial discordant test. However, all remnant serum or
plasma specimens with sufficient volume sent to CDC were
uniformly tested with a third-generation IgM-sensitive EIA, WB,
and NAAT. Though the ultimate HIV infection classification of
cases with repeat confirmatory testing appears to be correct, it is
possible that the use of pooled NAAT on serum (an off label use)
could have missed some early infections and resulted in
misclassification. Additionally, some persons with an indetermi-
nate repeat test result classified as uninfected could have been
misclassified because of relatively short retesting intervals (i.e.
insufficient time for seroconversion). However, of the 6 persons
whose indeterminate repeat test occurred less than the median
follow-up of 24 days, 3/3 were IFA negative and 3/3 were NAAT
negative. An additional limitation of the surveillance project is
potential under-reporting of discordant cases, though CDC staff
regularly contacted health departments to gauge whether all
discordant cases had been reported. Finally, another limitation is
that the tests utilized are limited to those available in the U.S. and
the testing guidelines mentioned are specific to the U.S., so results
may not be generalizable to other countries.
The findings from this post marketing surveillance project
underscore the need for rapid HIV testing programs to work with
persons with reactive rapid tests and negative or indeterminate
confirmatory test results to ensure that they have repeat
confirmatory testing on a new specimen obtained during a
follow-up visit. Due to the lower sensitivity of the WB performed
on oral fluid, confirmatory testing following a reactive rapid test
should be conducted using serum or plasma, when possible.
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